Table of Contents
Relevance tier by entity
| Entity | Tier | Description |
|---|---|---|
 |
2 | Role of KANK2 mutations in BL requires confirmation |
Mutation incidence in large patient cohorts (GAMBL reanalysis)
| Entity | source | frequency (%) |
|---|---|---|
| BL | GAMBL Exome | 2.874 |
| BL | GAMBL Genome | 1.544 |
| DLBCL | GAMBL Exome | 1.671 |
| DLBCL | GAMBL Genome | 0.188 |
| FL | GAMBL Exome | 0.287 |
| MCL | GAMBL Genome | 1.17 |
History
%%{init: { 'logLevel': 'debug', 'theme': 'dark' } }%%
timeline
title Publication timing
2012-10-04 : Schmitz : BL
References
1.
Schmitz R, Young RM, Ceribelli M, Jhavar S,
Xiao W, Zhang M, Wright G, Shaffer AL, Hodson DJ, Buras E, Liu X, Powell
J, Yang Y, Xu W, Zhao H, Kohlhammer H, Rosenwald A, Kluin P,
Müller-Hermelink HK, Ott G, Gascoyne RD, Connors JM, Rimsza LM, Campo E,
Jaffe ES, Delabie J, Smeland EB, Ogwang MD, Reynolds SJ, Fisher RI,
Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Pittaluga S,
Wilson W, Waldmann TA, Rowe M, Mbulaiteye SM, Rickinson AB, Staudt LM.
Burkitt lymphoma pathogenesis and therapeutic targets from structural
and functional genomics. Nature. 2012 Oct 4;490(7418):116–120. PMCID: PMC3609867
